For the secondary outcome at ITT follow-up, the ACE inhibitor group exhibited a higher risk of schizophrenia occurrence than the ARB group (summary HR 1.27 [95% CI, 1.07–1.51]; P =.006). Here, ACE is linked to schizophrenia.